Paramount Skydance Corporation (NASDAQ:PSKY) closed Monday's session up 1.4% at $10.28, extending a five-day rally of 9.6%, after the media conglomerate asked a judge to require opponents of its proposed $110 billion acquisition of Warner Bros. Discovery to post a $1.88 billion litigation bond. The filing, made in the California federal court overseeing the antitrust challenge, converts a procedural delay into a quantifiable financial risk for shareholders.
According to court documents, Paramount estimates that the ongoing legal dispute could generate up to $1.3 billion in unrecoverable ticking fees—payments owed to Warner shareholders if the merger closes after September 30. That figure represents roughly 34% of the company's $3.8 billion adjusted EBITDA guidance for 2026. The requested bond alone would cover about 49% of that same forecast, underscoring the materiality of the delay.
The litigation, led by a coalition of 12 state attorneys general, seeks to block the merger on antitrust grounds. A trial is scheduled for March, meaning the transaction could remain in limbo well beyond the September 30 deadline. After that date, Paramount owes Warner shareholders approximately $7 million per day in ticking fees, which would accumulate to the projected $1.3 billion before trial and final briefs conclude. These are company estimates, not a court award, but they highlight the escalating cost of waiting.
Investors have responded positively to Paramount's proactive legal strategy. Over the past five sessions, PSKY shares have climbed 9.6%, while Warner Bros. Discovery (NASDAQ:WBD) rose 3.2% during the same period. In comparison, streaming rival Netflix (NASDAQ:NFLX) gained 1.6%, and The Walt Disney Company (NYSE:DIS) remained flat. Monday's close saw WBD at $27.93, leaving a $3.07 gap to the $31 cash offer—an 11.0% gross spread before any ticking fee, indicating that the market still prices in substantial completion and timing risk.
Merger Economics Under Scrutiny
The merger terms, announced by both companies, include a $31 per share cash price for WBD, an enterprise value of $110 billion, and a committed new Class B equity investment of $47 billion at $16.02 per share—a 56% premium to PSKY's current close. The deal is expected to generate more than $6 billion in annual synergies, a central pillar of its financial rationale. However, the combined entity would open with net leverage of 4.3 times EBITDA, making the timely realization of synergies and deleveraging critical.
Paramount's chief legal officer, Makan Delrahim, has indicated that a possible sale of CNN remains “on the table,” which could serve as a negotiating asset to alleviate antitrust concerns and generate cash. A divestiture could reduce regulatory pressure, but it would also remove a scarce global news asset from the combined group. No buyer, price, or formal sale process has been announced, leaving Wall Street cautious.
Analyst sentiment reflects this caution. In a poll of 20 analysts by S&P Global, the average price target stands at $9.81, 4.6% below Monday's close. The consensus rating is Hold, with 50% of analysts recommending hold, 25% strong sell, and only 10% buy. Notable recent calls include Morgan Stanley's Sean Diffley reiterating a buy with a $10 target on August 6, Benchmark's Daniel Kurnos maintaining buy but cutting his target to $16, and Bank of America's Jessica Reif Ehrlich reiterating a sell with a $9 target.
What's Next
The week ahead will focus on court filings and any signals of a settlement. September 30 remains the harder financial marker, as each day after that transfers more value from Paramount to Warner holders. A settlement could close the spread quickly and support both stocks, while a prolonged injunction would increase fees, delay synergies, and require renewed regulatory approvals. In the worst case, failure of the merger would expose Paramount to a $7 billion regulatory termination payment.
For now, the litigation bond request is a strategic move to shift the cost of delay onto challengers, but it also crystallizes the financial stakes. With the trial set for March, the path to completion remains uncertain, and investors are weighing the potential rewards against the mounting risks.
